Liven Pharmaceuticals Income Statement

Financials in millions PKR. Fiscal year is July - June.

Millions PKR. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2019 - 2015
Cost of Revenue	64.1	-	-	-	-	0.32	Upgrade
Gross Profit	24.81	-	-	-	-	-0.32	Upgrade
Selling, General & Admin	2.61	2	2.12	2.95	2.1	1.85	Upgrade
Other Operating Expenses	-	-	-	-	-	17.84	Upgrade
Operating Expenses	14.4	13.79	15.22	17.51	18.19	19.69	Upgrade
Operating Income	10.41	-13.79	-15.22	-17.51	-18.19	-20.01	Upgrade
Other Non Operating Income (Expenses)	-	-	-0	-0	-0	-0	Upgrade
EBT Excluding Unusual Items	10.41	-13.79	-15.23	-17.51	-18.19	-20.02	Upgrade
Other Unusual Items	28.92	-	-	-	-	-	Upgrade
Pretax Income	124.75	-13.79	-15.23	-17.51	-18.19	-20.02	Upgrade
Income Tax Expense	-15.21	-2.61	-2.9	-3.22	-3.55	-3.09	Upgrade
Net Income	139.96	-11.18	-12.33	-14.29	-14.63	-16.93	Upgrade
Net Income to Common	139.96	-11.18	-12.33	-14.29	-14.63	-16.93	Upgrade
Shares Outstanding (Basic)	12	12	12	12	12	12	Upgrade
Shares Outstanding (Diluted)	32	12	12	12	12	12	Upgrade
Shares Change (YoY)	166.13%	-	-	-	-	-	Upgrade
EPS (Basic)	11.58	-0.92	-1.02	-1.18	-1.21	-1.40	Upgrade
EPS (Diluted)	4.34	-0.92	-1.02	-1.18	-1.21	-1.40	Upgrade
Free Cash Flow	-0.68	-0.88	-2.27	-2.26	-6.79	-1.89	Upgrade
Free Cash Flow Per Share	-0.02	-0.07	-0.19	-0.19	-0.56	-0.16	Upgrade
EBITDA	21.87	-2	-2.12	-2.95	-2.1	-2.14	Upgrade
D&A For EBITDA	11.46	11.79	13.1	14.56	16.08	17.87	Upgrade
EBIT	10.41	-13.79	-15.22	-17.51	-18.19	-20.01	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.